A year in the molecular life sciences: 2024 highlights.

The FEBS Journal editorial team reviews the articles we published in 2024 and reflects on the year's highlights. The articles summarised here broadly cluster in three themes-molecular and cell biology across species, immunology, and cutting-edge methods-whilst still showcasing the diversity of the scientific fields the journal covers. We look forward to many more excellent articles in 2025 and hope these highlights will inspire you to submit your next manuscript to The FEBS Journal.

Rewarding excellence: the 2024 FEBS Journal Richard Perham prize.

This editorial highlights and celebrates the winner of the 2024 Richard Perham prize. This was selected from shortlisted original articles that were published in The FEBS Journal in 2023 and received prize nominations from the Editorial Board. The winning paper, by Matteo Brindisi, Luca Frattaruolo, Federica Sotgia, Michael P Lisanti, Anna Rita Cappello and colleagues, shows how high cholesterol levels promote breast cancer aggressiveness.

Corrigendum: Microfluidic-based human prostate-cancer-on-chip.

[This corrects the article DOI: 10.3389/fbioe.2024.

There are dementia patients in Gaza too.

This editorial highlights the devastating impact of the ongoing Israeli military assault in Gaza on dementia patients, whose fragile care systems have collapsed, leaving them vulnerable and without essential medical support. Through harrowing stories of displacement, medication shortages, and tragic deaths, the piece underscores the profound moral failure in protecting Gaza's most vulnerable, calling for urgent global action to address the humanitarian crisis and ensure dignity and healthcare for all affected individuals.

Microfluidic Applications in Prostate Cancer Research.

Prostate cancer is a disease in which cells in the prostate, a gland in the male reproductive system below the bladder, grow out of control and, among men, it is the second-most frequently diagnosed cancer (other than skin cancer). In recent years, prostate cancer death rate has stabilized and, currently, it is the second-most frequent cause of cancer death in men (after lung cancer). Most deaths occur due to metastasis, as cancer cells from the original tumor establish secondary tumors in distant organs.